Treatment of genetic neutrophil disorders using patient-derived induced pluripotent stem cells (iPSCs) capable of producing functional neutrophils. Mature cells (fibroblasts or other cell types) could be obtained from the patient and reprogrammed into iPSCs using defined reprogramming factors. Following gene correction or repair, iPSCs could be expanded and differentiated in vitro using the Yokoyama et al or another similar protocol, modified to provide hematopoietic stem cells that are capable of producing functional neutrophils after autologous transplantation. Professional illustration by Marie Dauenheimer.